Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease

Endocrine Journal

Midori Ito¹  Masanori Abe¹  Yoshinori Yoshida¹  Masayoshi Soma¹  Noriaki Maruyama¹  Kazuyoshi Okada¹ 

[1] Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, 173-8610, Japan

关键词: Albuminuria;    Chronic kidney disease;    Cystatin C;    Malondialdehyde-modified LDL (MDA-LDL);    Rosuvastatin;   

DOI  :  10.1507/endocrj.K11E-080

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(31)Cited-By(11)We aimed to assess the effects of rosuvastatin treatment on lipid levels, albuminuria, and kidney function in patients with chronic kidney disease (CKD).We conducted a prospective, open-label, study of 91 patients with CKD, low-density lipoprotein cholesterol (LDL-C) levels > 120 mg/dL, and well-controlled blood pressure who were undergoing treatment with renin-angiotensin system inhibitors.Subjects were treated with 2.5 mg/day rosuvastatin, which was increased to 10 mg/day for the 24-week study period.Rosuvastatin effectively reduced total cholesterol, LDL-C, triglycerides, non-high density lipoprotein cholesterol (non-HDL-C) levels, and the LDL-C/HDL-C ratio.Although there was no significant change in the estimated glomerular filtration rate (eGFR), serum cystatin C levels and urinary albumin/creatinine ratio were significantly decreased.Subjects were divided into 2 groups: with and without diabetes mellitus (DM).Percent changes of HDL-C, C-reactive protein (CRP), and malondialdehyde-modified (MDA)-LDL were significantly higher in the DM group than in the non-DM group.Furthermore, when the subjects were divided into 2 groups based on eGFR levels (60 mL/min/1.73 m2 or more, normal-GFR group; less than 60 mL/min/1.73 m2, decreased-GFR group), the percent reduction of non-HDL-C, CRP, MDA-LDL levels, and albuminuria of DM subjects in the decreased-GFR group were significantly higher than those in the non-DM subjects.Multivariate analysis identified a change in cystatin C to be associated with decreased albuminuria during rosuvastatin treatment.Rosuvastatin administration reduced albuminuria, serum cystatin C levels, and inflammation, and improved lipid profiles, regardless of the presence or absence of DM, and the degree of the eGFR.

【 授权许可】

Unknown